Therapeutic Advances in Childhood Leukemia and Lymphoma Consortium (TACL) / Amgen Carfilzomib study

IRB
CCI-CG-06-00012
20140106 (formerly CFZ008); Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia

Carfilzomib (also known as Kyprolis®) is approved to be used in certain adult patients with relapsed or refractory multiple myeloma (myeloma that returns after a successful course of treatment or myeloma that does not respond to treatment). Multiple myeloma is a type of blood cancer. Carfilzomib is not approved to treat ALL. It has not been given in combination with the other drugs used in this study. This study is being done to find out if carfilzomib can be safely given before and during treatment with standard chemotherapy drugs.

Study Details
Clinical Trials Government Identifier
NCT02303821
Keywords
carfilzomib induction chemotherapy, chemotherapy, acute lymphoblastic leukemia, ALL, relapse, kyprolis, cancer
Study Type
Drug Treatment
Eligibility
Age 1 to 21 with leukemia (ALL) that has returned after an initial response to treatment or failed to respond to initial treatment
Does this study also recruit healthy volunteers?
No
Enrollment Status
Closed
Coordinator Contact
Ellynore Florendo
Contact Email
TACL@chla.usc.edu
Coordinator Contact
Meg Fender